Comparative Pharmacology
Head-to-head clinical analysis: CROLOM versus KETOTIFEN FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CROLOM versus KETOTIFEN FUMARATE.
CROLOM vs KETOTIFEN FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CROLOM is a selective estrogen receptor modulator (SERM) that binds to estrogen receptors, blocking estrogen-mediated signaling in target tissues, thereby inhibiting growth of hormone-sensitive breast cancer cells.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
2 capsules (each containing 40 mg cromolyn sodium) orally 4 times daily, 30 minutes before meals and at bedtime.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
None Documented
None Documented
Terminal half-life 8-12 hours in normal renal function; extended to 20-30 hours in severe impairment
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Category C
Category A/B
Mast Cell Stabilizer
Antihistamine / Mast Cell Stabilizer